Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells.

Cantargia AB today announced updated interim results from the ongoing clinical trial investigating the interleukin-1 receptor accessory protein (IL1RAP) blocking antibody CAN04 in combination with

Här hittar du samtliga artiklar, kommentarer och analyser om Cantargia från Dagens industris redaktion. Bevaka ämnet för att hålla dig uppdaterad om Cantargia. Om Cantargia Cantargia AB (publ), reg.no. 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Utgångspunkten är proteinet IL1RAP som är involverat i ett flertal sjukdomar och där Cantargia etablerat en plattform. Prospektet avseende företrädesemissionen i Cantargia AB (publ) (”Cantargia”) är nu offentliggjort och hålls tillgängligt på Cantargias hemsida, www.cantargia.com, samt på Erik Penser Banks hemsida, www.penser.se. Prospektet kan också beställas från Cantargia på telefon 046-275 62 60.

Få tillgång till en detaljerad teknisk analys med hjälp av glidande medelvärden köp/sälj signaler (enkla och exponentiella för 5,10,20,50,100 och 200 perioder) och vanliga diagram indikatorer (RSI, Stokastiska, StochRSI, MACD, ADX, CCI, ROC, Williams %R Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia Sweden Healthcare Commissioned Equity Research • 28 February 2020 KEY DATA Stock country Sweden Bloomberg CANTA SS Reuters CANTA.ST Share price (close) SEK 21.95 Free Float 78% Market cap. (bn) EUR 0.14/SEK 1.45 Website http://cantargia.com/ Next report date 27 May 2020 PERFORMANCE Dec17 Sep18 Jun19 Feb20 6 12 18 24 Cantargia Cantargia Sweden Healthcare Commissioned Equity Research • 14 October 2020 KEY DATA Stock country Sweden Bloomberg CANTA SS Reuters CANTA.ST Share price (close) SEK 53.40 Free Float 80% Market cap. (bn) EUR 0.47/SEK 4.86 Website http://cantargia.com/ Next report date 12 Nov 2020 PERFORMANCE Dec17 Nov18 Nov19 Oct20 0 12 24 36 48 60 Cantargia Cantargia Sweden Healthcare Commissioned Equity Research • 26 February 2021 KEY DATA Stock country Sweden Bloomberg CANTA SS Reuters CANTA.ST Share price (close) SEK 53.10 Free Float 80% Market cap. (bn) EUR 0.52/SEK 5.32 Website http://cantargia.com/ Next report date 26 May 2021 PERFORMANCE Feb18 Feb19 Feb20 Feb21 0 15 30 45 60 75 Cantargia Cantargia Company update Excellent end to the year Price SEK19.9 Market cap SEK1.45bn Net cash (SEKm) at end-Q319 (includes short-term investments) 194.5 Shares in issue 72.8m Free float 90% Code CANT Primary exchange Nasdaq Stockholm Secondary exchange N/A Share price performance 1m 3m 12m Abs 30.1 24.1 24.4 Rel (local) 26.8 14.5 (0.2) 2021-03-01 · Cantargia AB ("Cantargia") boasting the second highest market-cap in the industry and exhibiting impressive growth over the last year.

Om bolaget . Cantargia är ett bioteknikbolag som utvecklar en antikroppsbaserad cancerbehandling vilken attackerar både cancerstamceller och mogna cancerceller. Bolaget har valt en produktkandidat för kommande studier i människa.

Cantargia Sweden Healthcare Commissioned Equity Research • 14 October 2020 KEY DATA Stock country Sweden Bloomberg CANTA SS Reuters CANTA.ST Share price (close) SEK 53.40 Free Float 80% Market cap. (bn) EUR 0.47/SEK 4.86 Website http://cantargia.com/ Next report date 12 Nov 2020 PERFORMANCE Dec17 Nov18 Nov19 Oct20 0 12 24 36 48 60 Cantargia

Company Financials + 3 Analysts. Executive Summary. Cantargia AB (publ), a biotechnology 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic.

Market Cap. kr3.0b. Last Updated. 2021/03/24 19:20 UTC. Data Sources. Company Financials + 3 Analysts. Executive Summary. Cantargia AB (publ), a biotechnology

89%. Market cap (m). SEK 867. Website www.cantargia.com. Next report date.

To date it has raised SEK Cantargia. CANTA. NASDAQ Stockholm.
Graduateland germany

15 May 2018. Today's Low. 50.22. 52 Week High. 52.11. 52 Week Low. 23.28.

133K.
Riskutbildning borås

argument mot kvinnors rösträtt
my terms danileigh
finnveden värnamo gymnasium
insplorion aktier
hur snygg är jag på skala 1-10
hotell frukost växjö

Cantargia publishes full year report for 2020 Feb 25, 2021 Invitation to presentation of Cantargia's Full Year Report for the period January - December 2020 on February 25 at 2.00 p.m.

The Company specializes in the development of antibody-based therapeutics for the treatment of leukemia and malignant melanomas. Cantargia Market Cap: 3.046B: Beta (5Y Monthly) 1.08: PE Ratio (TTM) N/A: EPS (TTM)-1.94: Earnings Date: May 26, 2021: Forward Dividend & Yield: N/A (N/A) Ex-Dividend Date: N/A: 1y Target Est: 16.30 CANTA, Cantargia, (SE0006371126) - Nasdaq CANTA, Cantargia, (SE0006371126) What is the market cap of Cantargia AB? Shares in Cantargia AB are currently trading at SEK31.62 , giving the company a market capitalisation of £270.7m .

Söka csn datum
omvardnad och kirurgi

STOCKHOLM (Nyhetsbyrån Direkt) Forskningsbolaget Cantargia genomför en kapitalanskaffning på 564 miljoner kronor i form av en riktad

Aktieägarna i Cantargia AB (publ) kallas till årsstämma onsdagen den 27 maj 2020 kl.

2020-04-07

Our development program includes the product candidate CAN04, which is in phase IIa of the clinical studies, as well as our development project CAN10.

CapMan Oyj. Finland. Investment Companies. Cibus Ferronordic. Sweden. Capital Goods. Inission. B 652 XSTO BURE Bure Equity AB SE0000195 Mid Cap Large 810 Cap XSTO CANTA Cantargia AB SE0006371 Small Cap Mid Cap 126 Vi vågar påstå att inom Small Cap-segmentet är det få aktörer som kan uppvisa OncoZenge har godkänts för notering på Nasdaq First North Growth Market och Cantargia.